Статья
Коронавирусная инфекция - актуальная проблема XXI века
В декабре 2019 г. в Китае зарегистрирована серия необъяснимых случаев пневмонии. Последующие исследования выявили новый штамм коронавируса - SARS-CoV-2, который является возбудителем острого инфекционного заболевания Coronavirus disease 2019 (COVID-19). За короткий период времени эпидемия новой коронавирусной инфекции переросла в пандемию, охватившую более 200 стран мира. Представленный обзор включает актуальные данные по этиологии, эпидемиологии, патогенезу, клиническим проявлениям, принципам диагностики и лечения коронавирусной инфекции нового типа, а также отражает представления о влиянии COVID-19 на сердечно-сосудистую систему.
1. Su S., Wong G., Shi W., Liu J., Lai A.C.K., Zhou J. et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24: 490-502. doi: 10.1016/j.tim.2016.03.003.
2. Singhal T. A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020; 87(4): 281-286. doi: 10.1007/s12098-020-03263-6.
3. Министерство здравоохранения Российской Федерации. Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Временные методические рекомендации Версия 4.0 (27.03.20). Режим доступа: https://urlid.ru/c30s (дата обращения 16.04.2020).
4. Chen Y, Liu Q., Guo D. Emerging coronaviruses: Genome structure, replication, and pathogenesis. J Med Virol. 2020; 92(4):418-423. doi: 10.1002/jmv.25681.
5. Cui J., Li F., Shi Z.L. Origin and evolution of pathogenic coronaviruses. Nat Rev Microbiol. 2019; 17: 181-192.
6. Chan K.S., Zheng J.P., Mok Y.W., Li Y.M., Liu Y.N., Chu C.M. et al. SARS: prognosis, outcome and sequelae. Respirology. 2003; 8(Suppl): 36-40. doi:10.1046/j.1440-1843.2003.00522.x
7. Badawi A., Ryoo S.G. Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis. J Public Health Res. 2016; 5(3): 733. doi: 10.4081/jphr.2016.733.
8. Li B., Yang J., Zhao F., Zhi L., Wang X., Liu L. et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020. doi: 10.1007/s00392-020-01626-9.
9. Sun P., Lu X., Xu C., Sun W., Pan B. Understanding of COVID-19 based on current evidence. J Med Virol. 2020. doi: 10.1002/jmv.25722.
10. Стопкоронавирус.рф. Режим доступа: https:// xn--80aesfpebagmfblc0a.xn--p1ai/# (дата обращения 16.04.2020).
11. Sanders J.M., Monogue M.L., Jodlowski T.Z., Cutrell J.B. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020. doi: 10.1001/jama.2020.6019.
12. Han Y., Yang H. The transmission and diagnosis of 2019 novel coronavirus infection disease (COVID-19): a Chinese perspective. J Med Virol. 2020. doi: 10.1002/jmv.25749.
13. Tan W., Aboulhosn J. The cardiovascular burden of coronavirus disease 2019 (COVID-19) with a focus on congenital heart disease. Int J Cardiol. 2020. doi: 10.1016/j.ijcard.2020.03.063.
14. Bai Y., Yao L., Wei T. Presumed asymptomatic carrier transmission of COVID-19. JAMA. 2020; 21: 19-20.
15. Mizumoto K., Kagaya K., Zarebski A. Estimating the asymptomatic proportion of coronavirus disease 2019 (COVID-19) cases on board the Diamond Princess cruise ship, Yokohama, Japan, 2020. Eurosurveillance. 2020; 25(10): 2000180. doi: 10.2807/1560-7917.ES.2020.25.10.2000180.
16. Li Q., Guan X., Wu P., Zhou L., Tong Y, Ren R. et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. N Engl J Med. 2020; 382(13): 1199-1207. doi:10.1056/NEJMoa2001316.
17. Flahault A. Has China faced only a herald wave of SARS-CoV-2? Lancet. 2020; 395(10228): 947. doi: 10.1016/S0140-6736(20)30521-3 49.
18. Cobum B.J., Wagner B.G., Blower S. Modeling influenza epidemics and pandemics: insights into the future of swine flu (H1N1). BMC Med. 2009; 7(1): 30. doi: 10.1186/1741-7015-7-30.
19. Menachery V.D., Yount B.L., Debbink K., Agnihothram S., Gralinski L.E., Plante J.A. et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence. Nat. Med. 2015; 21(12): 1508-1513. doi: 10.1038/nm.3985.
20. Wan Y, Shang J., Graham R., Baric R.S., Li F. Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS. J Virol. 2020; 94(7): 1-9. doi: 10.1128/jvi.00127-20.
21. Jia H.P, Look D.C., Shi L., Hickey M., Pewe L., Netland J. et al. ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia. J Virol. 2005; 79(23): 14614-14621. doi: 10.1128/jvi.79.23.14614-14621.2005.
22. Sodhi C.P., Wohlford-Lenane C., Yamaguchi Y, Prindle T., Fulton W.B., Wang S. et al. Attenuation of pulmonary ACE2 activity impairs inactivation of des-Arg9 bradykinin/BKB1R axis and facilitates LPS-induced neutrophil infiltration. Am J Physiol Lung Cell Mol Physiol. 2018; 314(1): 17-31. doi: 10.1152/ajplung.00498.2016.
23. Chen N., Zhou M., Dong X., Qu J., Gong F., Han Y et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395(10223): 507-513. doi: 10.1016/S0140-6736(20)30211-7.
24. Oudit G.Y, Kassiri Z., Jiang C., Liu P.P., Poutanen S. M., Penninger J.M. et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009; 39(7): 618-625. doi: 10.1111/j.1365-2362.2009.02153.x.
25. Short K.R., Kroeze E.J.B.V., Fouchier R.A.M., Kuiken T. Pathogenesis of influenza-induced acute respiratory distress syndrome. Lancet Infect Dis. 2014; 14(1): 57-69. doi: 10.1016/ S1473-3099(13)70286-X.
26. Mora R., Arold S., Marzan Y, Suki B., Ingenito E.P Determinants of surfactant function in acute lung injury and early recovery. Am J Physiol Lung Cell Mol Physiol. 2000; 279(2): 342-349. doi:10.1152/ajplung.2000.279.2.l342.
27. Guan W.J., Ni Z.Y., Hu Y, Liang W.H., Ou C.Q., He J.X. et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020. doi: 10.1056/NEJMoa2002032.
28. Yang X., Yu Y, Xu J., Shu H., Xia J., Liu H. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 2600(20): 1-7. doi: https://doi.org/10.1016/S2213-2600(20)30079-5.
29. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии COVID-19. Режим доступа: https://urlid.ru/c30r (дата обращения 18.04.2020).
30. Анестезиолого-реанимационное обеспечение пациентов с новой коронавирусной инфекцией COVID-19: ключевые положения. Версия 1 от 07 апреля 2020 года. Методические рекомендации. Режим доступа: https://urlid.ru/c30q (дата обращения 18.04.2020).
31. Li L.Q., Huang T., Wang Y.Q., Wang Z.P., Liang Y, Huang T.B. et al. COVID-19 patients' clinical characteristics, discharge rate and fatality rate of meta-analysis. J Med Virol. 2020. doi: 10.1002/jmv.25757.
32. Huang C., Wang Y, Li X., Ren L., Zhao J., Hu Y et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223): 497506. doi: 10.1016/S0140-6736(20)30183-5.
33. Wang D., Hu B., Hu C., Zhu F., Liu X., Zhang J. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020. doi: 10.1001/jama.2020.1585.
34. Zhou F., Yu T., Du R., Fan G., Liu Y, Liu Z. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229): 1054-1062. doi: 10.1016/S0140-6736(20)30566-3.
35. Driggin E., Madhavan M.V., Bikdeli B., Chuich T., Laracy J., Bondi-Zoccai G. et al. Cardiovascular considerations for patients, health care workers, and health systems during the coronavirus disease 2019 (COVID-19) pandemic. J Am Coll Cardiol. 2020. doi: 10.1016/j.jacc.2020.03.031.
36. Li F., Li W., Farzan M., Harrison S.C. Structure of SARS coronavirus spike receptor-binding domain complexed with receptor. Science. 2005; 309(5742): 1864-1868. doi:10.1126/science.1116480.
37. Lu R., Zhao X., Li J., Niu P., Yang B., Wu H. et al. Genomic characterization and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020; 395(10224): 565-574. doi: 10.1016/S0140-6736(20)30251-8.
38. Xu Z., Shi L., Wang Y, Zhang J., Huang L., Zhang C. et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020; 8(4): 420-422. doi: 10.1016/S2213-2600(20)30076-X.
39. Lippi G., Lavie C.J., Sanchis-Gomar F. Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): Evidence from a meta-analysis. Prog Cardiovasc Dis. 2020. doi: 10.1016/j.pcad.2020.03.001.
40. Zhou P, Yang X.L., Wang X.G., Hu B., Zhang L., Zhang W. et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798): 270-273. doi: 10.1038/s41586-020-2012-7.
41. Thygesen K., Alpert J.S., Jaffe A.S., Chaitman B,R,, Bax J.J., Morrow D.A. et al. Fourth universal definition of myocardial infarction (2018). J Am Coll Cardiol. 2018; 72: 2231-2264. doi: 10.1016/j.jacc.2018.08.1038.
42. Buzon J., Roignot O., Lemoine S., Perez P, Kimmoun A., Levy B. et al. Takotsubo cardiomyopathy triggered by influenza A virus. Intern Med. 2015; 54(16): 2017-2019. doi: 10.2169/internalmedicine.54.3606.
43. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18(4): 844-847. doi: 10.1111/jth.14768.
44. Fan B.E., Chong V.C.L., Chan S.S.W, Lim G.H., Lim K.G.E., Tan G.B. et al. Hematologic parameters in patients with COVID-19 infection. Am J Hematol. 2020. doi: 10.1002/ajh.25774.
45. KALETRA(R) oral film coated tablets, oral solution, lopinavir ritonavir oral film coated tablets, oral solution. Product Insert. AbbVie Inc. (per FDA), North Chicago, IL, 2013. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/la bel/2013/021251s046_021906s039lbl.pdf (accessed 13.04.2020)
46. DeCarolis D.D., Westanmo A.D., Chen Y.C., Boese A.L., Walquist M.A., Rector T.S. Evaluation of a potential interaction between new regimens to treat hepatitis C and warfarin. Ann Pharmacother. 2016; 50(11): 909-917. doi: 10.1177/1060028016660325.
47. Frost C.E., Byon W., Song Y, Wang J., Schuster A.E., Boyd R.A. et al. Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. Br J Clin Pharmacol. 2015; 79(5): 838-846. doi: 10.1111/bcp.12541.
48. Mueck W., Kubitza D., Becka M. Co-administration of rivaroxaban with drugs that share itselimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013; 76(3): 455-466. doi: 10.1111/bcp.12075.
49. Itkonen M.K., Tornio A., Lapatto-Reiniluoto O., Neuvonen M., Neuvonen PJ.,Niemi M. et al. Clopidogrel increases dasabuvir exposure with or without ritonavir, and ritonavir inhibits the bioactivation of clopidogrel. Clin Pharmacol Ther. 2019; 105(1): 219-228. doi: 10.1002/cpt.1099.
50. Marsousi N., Daali Y., Fontana P, Reny J.L., Ancrenaz-Sirot V, Calmy A. et al. Impact of boosted antiretroviral therapy on the pharmacokinetics and efficacy of clopidogrel and prasugrel active metabolites. Clin Pharmacokinet. 2018; 57(10): 1347-1354. doi: 10.1007/s40262-018-0637-6.
51. Mulangu S., Dodd L.E., Davey R.T., Tshiani Mbaya O., Proschan M., Mukadi D. et al. A randomized, controlled trial of ebola virus disease therapeutics. N Engl J Med. 2019; 381(24): 2293-2303. doi: 10.1056/NEJMoa1910993.
52. Wrapp D., Wang N., Corbett K.S. Goldsmith J.A.., Hsieh C.L., Abiona O. et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science. 2020; 367(6483): 1260-1263. doi: 10.1126/science.abb2507.
53. Patel V.B., Zhong J.C., Grant M.B., Oudit G.Y. Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure. Circ Res. 2016; 118(8): 1313-1326. doi:10.1161/CIRCRESAHA.116.307708.